Ironwood Pharmaceuticals, Inc. (IRWD) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1156238,
    "name": "Ironwood Pharmaceuticals, Inc.",
    "stock_name": "Ironwood Pharmaceuticals, Inc.",
    "full_name": "Ironwood Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/ironwood-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "3.73",
    "chg": 0.23,
    "chgp": "6.57%",
    "dir": 1,
    "prev_price": "3.50",
    "mcapval": "183.55",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US46333X1081",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "3.56 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ironwood-pharmaceuticals-inc-1156238-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Ironwood Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ironwood-pharmaceuticals-forms-golden-cross-signaling-potential-bullish-breakout-3648898",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/IronwoodPharmac_goldencross_3648898.png",
        "date": "2025-10-27 15:17:33",
        "description": "Ironwood Pharmaceuticals has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock's daily moving averages suggest a bullish trend, with a notable performance increase over the past week. Despite earlier challenges, recent gains may signal a turning point for the company."
      },
      {
        "title": "Is Ironwood Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ironwood-pharmaceuticals-inc-technically-bullish-or-bearish-3547124",
        "imagepath": "",
        "date": "2025-09-20 19:47:39",
        "description": "As of 13 June 2025, the technical trend for Ironwood Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall. Key indicators include a mildly bullish MACD on both weekly and monthly time frames, a bullish RSI on the monthly, and a mildly bearish daily moving average. However, the Bollinger Bands show a bullish weekly but a mildly bearish monthly trend, and the KST indicates a bullish weekly but bearish monthly stance. The Dow Theory supports a mildly bullish view on both weekly and monthly time frames. \n\nIn terms of multi-period returns, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -67.04% versus 12.22% for the index, and a one-year return of -67.70% compared to 17.14%...."
      },
      {
        "title": "Is Ironwood Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ironwood-pharmaceuticals-inc-overvalued-or-undervalued-3543556",
        "imagepath": "",
        "date": "2025-09-20 18:22:33",
        "description": "As of 8 August 2023, the valuation grade for Ironwood Pharmaceuticals, Inc. has moved from expensive to risky, indicating a shift towards a more cautious outlook. The company appears to be overvalued given its negative price-to-book value of -0.29, an EV to EBITDA ratio of 6.72, and a high ROCE of 57.96%, which may not be sustainable in the long term. In comparison, a peer like Ironwood has a P/E ratio of 13.855, suggesting that the market may be pricing other companies in the industry more favorably.\n\nThe stock has experienced significant underperformance compared to the S&P 500, with a year-to-date return of -67.04% versus the S&P 500's 12.22%. This stark contrast reinforces the notion that Ironwood Pharmaceuticals is currently overvalued in the market...."
      }
    ],
    "total": 8,
    "sid": "1156238",
    "stock_news_url": "https://www.marketsmojo.com/news/ironwood-pharmaceuticals-inc-1156238"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Ironwood Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout

2025-10-27 15:17:33

Ironwood Pharmaceuticals has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock's daily moving averages suggest a bullish trend, with a notable performance increase over the past week. Despite earlier challenges, recent gains may signal a turning point for the company.

Is Ironwood Pharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 19:47:39

As of 13 June 2025, the technical trend for Ironwood Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall. Key indicators include a mildly bullish MACD on both weekly and monthly time frames, a bullish RSI on the monthly, and a mildly bearish daily moving average. However, the Bollinger Bands show a bullish weekly but a mildly bearish monthly trend, and the KST indicates a bullish weekly but bearish monthly stance. The Dow Theory supports a mildly bullish view on both weekly and monthly time frames. In terms of multi-period returns, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -67.04% versus 12.22% for the index, and a one-year return of -67.70% compared to 17.14%....

Is Ironwood Pharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 18:22:33

As of 8 August 2023, the valuation grade for Ironwood Pharmaceuticals, Inc. has moved from expensive to risky, indicating a shift towards a more cautious outlook. The company appears to be overvalued given its negative price-to-book value of -0.29, an EV to EBITDA ratio of 6.72, and a high ROCE of 57.96%, which may not be sustainable in the long term. In comparison, a peer like Ironwood has a P/E ratio of 13.855, suggesting that the market may be pricing other companies in the industry more favorably. The stock has experienced significant underperformance compared to the S&P 500, with a year-to-date return of -67.04% versus the S&P 500's 12.22%. This stark contrast reinforces the notion that Ironwood Pharmaceuticals is currently overvalued in the market....

View All News